Literature DB >> 20380629

Bone disease in diabetes.

M Luisa Isidro1, Belén Ruano.   

Abstract

The relationship between diabetes and bone disease is complex. While low bone mineral density (BMD) is consistently observed in type 1 diabetes (T1DM), in type 2 diabetes (T2DM) bone mineral density is similar to or higher than in non diabetic subjects. Yet, for both types of diabetes bone appears to be more fragile for a given density. Recent meta-analyses and cohort studies confirm that T1DM and T2DM are associated with higher fracture risk. Many factors influence the probability of fractures. Diabetes can affect bone through multiple pathways including obesity, changes in insulin levels, higher concentrations of advanced glycation end products in collagen, increased urinary excretion coupled with lower intestinal absorption of calcium, inappropriate homeostatic response of parathyroid hormone secretion, complex alterations of vitamin D regulation, reduced renal function, lower insulin-like growth factor-I, microangiopathy, and inflammation. Data on cellular mechanisms and experimental models are extensive, but the relevance of each one of these factors to the clinical situation is unclear. In this article we review the pathophysiological mechanisms potentially involved in the altered BMD found in diabetic patients, show data on the increased risk of fractures, and speculate on the potential causes of the increased risk of fractures in this context. Finally, we comment on the prevention and treatment of osteoporosis in diabetes, although the lack of trials testing the use of pharmacotherapy on preventing fractures in this context is emphasized.

Entities:  

Mesh:

Year:  2010        PMID: 20380629     DOI: 10.2174/157339910791162970

Source DB:  PubMed          Journal:  Curr Diabetes Rev        ISSN: 1573-3998


  37 in total

Review 1.  Type 2 diabetes and bone fractures.

Authors:  Kendall F Moseley
Journal:  Curr Opin Endocrinol Diabetes Obes       Date:  2012-04       Impact factor: 3.243

2.  Runx2 regulates the gene network associated with insulin signaling and energy homeostasis.

Authors:  Mitra Adhami; Farah Y Ghori-Javed; Haiyan Chen; Soraya E Gutierrez; Amjad Javed
Journal:  Cells Tissues Organs       Date:  2011-05-20       Impact factor: 2.481

3.  Local Application of Isogenic Adipose-Derived Stem Cells Restores Bone Healing Capacity in a Type 2 Diabetes Model.

Authors:  Christoph Wallner; Stephanie Abraham; Johannes Maximilian Wagner; Kamran Harati; Britta Ismer; Lukas Kessler; Hannah Zöllner; Marcus Lehnhardt; Björn Behr
Journal:  Stem Cells Transl Med       Date:  2016-04-21       Impact factor: 6.940

Review 4.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

5.  Socioeconomic status in relation to incident fracture risk in the Study of Women's Health Across the Nation.

Authors:  C J Crandall; W Han; G A Greendale; T Seeman; P Tepper; R Thurston; C Karvonen-Gutierrez; A S Karlamangla
Journal:  Osteoporos Int       Date:  2014-02-07       Impact factor: 4.507

Review 6.  Bariatric Surgery: Bad to the Bone, Part 1.

Authors:  Lara Pizzorno
Journal:  Integr Med (Encinitas)       Date:  2016-03

Review 7.  Adipose tissue dysfunction and its effects on tumor metabolism.

Authors:  Jonathan Diedrich; Halina Chkourko Gusky; Izabela Podgorski
Journal:  Horm Mol Biol Clin Investig       Date:  2015-01

8.  Prevalence of causes of secondary osteoporosis and contribution to lower bone mineral density in HIV-infected patients.

Authors:  J L Casado; S Bañon; R Andrés; M J Perez-Elías; A Moreno; S Moreno
Journal:  Osteoporos Int       Date:  2013-09-21       Impact factor: 4.507

9.  Homocysteine, an additional factor, is linked to osteoporosis in postmenopausal women with type 2 diabetes.

Authors:  Li Jianbo; Hongman Zhang; Lingfei Yan; Min Xie; Yan Mei; Chen Jiawei
Journal:  J Bone Miner Metab       Date:  2013-12-24       Impact factor: 2.626

10.  SGLT2 inhibitor therapy improves blood glucose but does not prevent diabetic bone disease in diabetic DBA/2J male mice.

Authors:  Kathryn M Thrailkill; R Clay Bunn; Jeffry S Nyman; Mallikarjuna R Rettiganti; Gael E Cockrell; Elizabeth C Wahl; Sasidhar Uppuganti; Charles K Lumpkin; John L Fowlkes
Journal:  Bone       Date:  2015-07-23       Impact factor: 4.398

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.